NFE2L2-Associated Ferroptosis Resistance Reshapes the Tumor Immune Microenvironment and Guides Therapeutic Strategies in Prostate Cancer
International Journal of Molecular Sciences · 15.05.2026 · 27 (10) · 4448
DOI: 10.3390/ijms27104448 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.05.2026. Verfasst von Yihan Lin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Clinical Research Center for Oral Diseases of Zhejiang Province,…. Hauptthemen laut MEDLINE: Ferroptosis, Prostatic Neoplasms, Tumor Microenvironment, NF-E2-Related Factor 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China.
Abstract (Originalsprache)
Prostate adenocarcinoma (PRAD) poses a significant challenge due to therapy resistance and an immunosuppressive tumor microenvironment (TME). Ferroptosis has emerged as a therapeutic vulnerability, yet its immunomodulatory role in PRAD remains elusive. Here, we employed a multi-omics approach—integrating bulk RNA-seq (498 tumors), single-cell RNA-seq (68,322 cells), and spatial transcriptomics (19,483 spots)—to decode the ferroptosis-immune landscape. We derived a robust 16-gene ferroptosis signature that predicted biochemical recurrence (C-index = 0.76) and validated it in two independent cohorts. Crucially, high-risk tumors exhibited a “cold” immunosuppressive TME enriched in regulatory T cells and M2 macrophages, alongside elevated immune checkpoints (HAVCR2, CTLA4, PDCD1). Single-cell and virtual knockout analyses revealed that cancer epithelial cells evade ferroptosis via NFE2L2-associated antioxidant defenses, which strongly correlates with immune exclusion. Spatial transcriptomics further demonstrated spatially organized vulnerabilities, with ferroptosis-resistant tumor cores and immune-infiltrated invasive margins. To identify therapeutic interventions, we utilized drug response modeling and molecular docking, prioritizing RSL3, Atovaquone (targeting NOX4 (NADPH oxidase 4)/DHODH), and Sorafenib (targeting TrxR1 (thioredoxin reductase 1, encoded by TXNRD1)) as potent agents with potential ferroptosis-modulatory activity. Collectively, our findings demonstrate that NFE2L2-associated ferroptosis resistance shapes immune evasion in PRAD. Targeting ferroptosis regulators provides a compelling therapeutic rationale to remodel the TME and synergize with immune checkpoint blockade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Clinical Research Center for Oral Diseases of Zhejiang Province, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Canc…
ORCID-Profile: Chengze Wang
Förderung
- the National Natural Science Foundation of China
Zitieren
APA
Lin, Y., Yu, H., Wang, Y., & Wang, C. (2026). NFE2L2-Associated Ferroptosis Resistance Reshapes the Tumor Immune Microenvironment and Guides Therapeutic Strategies in Prostate Cancer. International Journal of Molecular Sciences, 27(10), 4448. https://doi.org/10.3390/ijms27104448
Vancouver
Lin Y, Yu H, Wang Y, Wang C. NFE2L2-Associated Ferroptosis Resistance Reshapes the Tumor Immune Microenvironment and Guides Therapeutic Strategies in Prostate Cancer. International Journal of Molecular Sciences. 2026;27(10):4448. doi:10.3390/ijms27104448
BibTeX
@article{Lin2026,
author = {Lin, Yihan and Yu, Haojie and Wang, Ying and Wang, Chengze},
title = {NFE2L2-Associated Ferroptosis Resistance Reshapes the Tumor Immune Microenvironment and Guides Therapeutic Strategies in Prostate Cancer},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {10},
pages = {4448},
doi = {10.3390/ijms27104448}
}
EUVIMED